Phthalazinone derivatives

Details Phthalazinone derivatives Phthalazinone derivatives

2005-12-23

2010-02-16

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S183000, C514S247000, C544S233000, C544S235000, C544S237000, C546S001000, C546S026000, C546S112000

Reexamination Certificate

active

07662818

ABSTRACT:
Compounds of the formula (I):wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRXor CRXRY; if X=NRXthen n is 1 or 2 and if X=CRXRYthen n is 1; RXis selected from the group consisting of H, optionally substituted C1-20alkyl, C5-20aryl, C3-20heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RYis selected from H, hydroxy, amino; or RXand RYmay together form a spiro-C3-7cycloalkyl or heterocyclyl group; RC1and RC2are both hydrogen, or when X is CRXRY, RC1, RC2, RXand RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1is selected from H and halo.

REFERENCES:
patent: 3813384 (1974-05-01), Vogelsang et al.
patent: 4665181 (1987-05-01), Thomas et al.
patent: 4841047 (1989-06-01), Engel et al.
patent: 5032617 (1991-07-01), Lee et al.
patent: 5041653 (1991-08-01), Lee et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 5556856 (1996-09-01), Engel et al.
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5648355 (1997-07-01), Theoharides
patent: 5874444 (1999-02-01), West
patent: 5886178 (1999-03-01), Allen et al.
patent: 6197785 (2001-03-01), Jackson et al.
patent: 6340684 (2002-01-01), Napoletano et al.
patent: 6426415 (2002-07-01), Jackson et al.
patent: 6476048 (2002-11-01), Szabo et al.
patent: 6498160 (2002-12-01), Napoletano et al.
patent: 6514983 (2003-02-01), Li
patent: 6514984 (2003-02-01), Watanabe
patent: 6635642 (2003-10-01), Jackson et al.
patent: 6677333 (2004-01-01), Seko et al.
patent: 2002/0183325 (2002-12-01), Martin et al.
patent: 2004/0023968 (2004-02-01), Martin et al.
patent: 2005/0059663 (2005-03-01), Martin et al.
patent: 2005/0080096 (2005-04-01), Ishida et al.
patent: 2005/0227919 (2005-10-01), Kudos
patent: 2143745 (1973-03-01), None
patent: 3813531 (1988-04-01), None
patent: 287 032 (1991-02-01), None
patent: 0030861 (1981-06-01), None
patent: 0269968 (1988-06-01), None
patent: 0355750 (1990-02-01), None
patent: 0389995 (1990-10-01), None
patent: 0502575 (1992-09-01), None
patent: 0590551 (1994-04-01), None
patent: 0634404 (1995-01-01), None
patent: 0699754 (1996-03-01), None
patent: 0705903 (1996-04-01), None
patent: 0792643 (1997-09-01), None
patent: 2262513 (1975-09-01), None
patent: 721286 (1955-01-01), None
patent: 2384776 (2004-03-01), None
patent: MI98A001671 (1999-04-01), None
patent: 54156526 (1979-12-01), None
patent: 58164577 (1983-09-01), None
patent: 62-252774 (1987-11-01), None
patent: WO 91/18591 (1991-12-01), None
patent: WO 93/14086 (1993-07-01), None
patent: WO 94/10151 (1994-05-01), None
patent: WO 95/24379 (1995-09-01), None
patent: WO 96/19225 (1996-06-01), None
patent: WO 98/43477 (1998-10-01), None
patent: WO 98/51308 (1998-11-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11624 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/44612 (1999-09-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 00/05219 (2000-02-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 00/44726 (2000-08-01), None
patent: WO 00/67734 (2000-11-01), None
patent: WO 01/12199 (2001-02-01), None
patent: WO 01/16136 (2001-03-01), None
patent: WO 01/16137 (2001-03-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO 01/23390 (2001-04-01), None
patent: WO 01/57038 (2001-08-01), None
patent: WO 01/79184 (2001-10-01), None
patent: WO 01/85686 (2001-11-01), None
patent: WO 01/85687 (2001-11-01), None
patent: WO 01/87845 (2001-11-01), None
patent: WO 01/90077 (2001-11-01), None
patent: WO 02/36576 (2002-05-01), None
patent: WO 03/070726 (2002-05-01), None
patent: WO 02/44157 (2002-06-01), None
patent: WO 02/068407 (2002-09-01), None
patent: WO 02/090334 (2002-11-01), None
patent: WO 02/094790 (2002-11-01), None
patent: WO 03/007959 (2003-01-01), None
patent: WO 03/051879 (2003-06-01), None
patent: WO 03/055865 (2003-07-01), None
patent: WO 03/057145 (2003-07-01), None
patent: WO 03/063874 (2003-08-01), None
patent: WO 03/070707 (2003-08-01), None
patent: WO 03/080581 (2003-10-01), None
patent: WO 03/093261 (2003-11-01), None
patent: WO 2004/080976 (2004-09-01), None
patent: WO 2005/053662 (2005-06-01), None
Wolff, M.E., “Burger's Medicinal Chemistry”, 5thEd., Part 1, pp. 975-977 (1995).
Banker et al., “Modern Pharmaceuticals”, 3rdEd., p. 596 (1996)/.
Vippagenta et al., “Crystalline solids”, Advance Drug Deliver Reviews 48 (2001) 3-26.
Pinedo et al, “Translational Research . . . ”, The Oncologist 2000; 5(suppI1); 1-2. [www.The Oncologist.com].
McMahon, G., VEGF Receptor Signaling in Tumor Angiogenisis. The Oncologist 2000;5(suppl 1):3-10. [www.TheOncologist.com].
U.S. Appl. No. 11/873,671, filed Oct. 17, 2007, entitled “Phthalazinone Derivative.”
Bloch, et al. “Poly-adenosine diphosphate-ribose polymerase inhibition for myocardial protection: Pathophysiologic and physiologic considerations,”Journal of Thoracic and Cardiovascular Surgery, Year 2004; vol. 128; pp. 323-324.
Cockcroft, et al. “Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose) polymerase,”Bioorganic&Medicinal Chemistry Letters, Year Feb. 2006; vol. 16; Issue 4; pp. 1040-1044.
Cuzzocrea, “Shock, inflammation and PARP,”Pharmacological Research, Year Jul. 2005; vol. 52; Issue 1; pp. 72-82.
Loh, et al., “Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose) polymerase,”Bioorganic&Medicinal Chemistry Letters, Year May 2, 2005; vol, 15; Issue 9; pp. 2235-2238.
Miller, “Inhibition of TRPM2 function by PARP inhibitors protects cells from oxidative stress-induced death,”British Journal of Pharmacology, Year 2004; vol. 143; pp. 515-516.
Szabó, et al., “Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest,”Journal of Thoracic and Cardiovascular Surgery, Year 2003; vol. 126; pp. 651-658.
Tasatargil, et al., “Poly(ADP-Ribose) Polymerase Inhibition Prevents Homocysteine-lnduced Endothelial Dysfunction in the Isolated Rat Aorta,”Pharmacology International Journal of Experimental and Clinical Pharmacology, Year 2004; vol. 72; pp. 99-105.
Affar, E. B. et al.,Anal. Biochem., 1998, vol. 259, No. 2, 280-3.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.”Archives of toxicology, Supplement.Archiv fur Toxikologie. Supplement, vol. 7, 219-231 (1984).
Ame et al.,J. Biol. Chem., 1999, vol. 274, 17860-17868.
Ame, Bioessays (2004) 26(8):882-893.
Angell et al.,EMBO J., 1997, vol. 16, No. 12, 3675-3684.
Arnaudeau, C. et al.,J. Mol. Biol, 2001, vol., 307, 1235-45.
Banasik, M. et al., “Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferse”,J. Biol. Chem., 1992, vol. 267, 1569-1575.
Banasik, M. et al.,Mol. Cell Biochem., 1994, vol. 138, 185-197.
Ben-Hur et al., 1984,British Journal of Cancer, 49 (Suppl. VI): 39-42.
Berge et al., 1977, “Pharmaceutically Acceptable Salts,”J. Pharm. Sci., vol. 66, 1-19. Protective Groups in Organic Synthesis (T. Green and P. Wuts, Wiley, 1991).
Berger, N. A. et al., “Poly (ADP-ribose) in cellular response toNAna damage”,Radiation Research, 1985, vol. 101, 4-14.
Bhattacharyya, A. et al.,J. Biol. Chem., 2000, vol. 275, 23899-903.
Bold et. al.,. Med. Chem., 2000, 43, 3200.
Bold, G. et al., “New anilinophthalazines as potent and orally well absorbed inhibitors of the FEBF receptor tyrosine kinases useful as antagonists of tumour-driven angiogenesis”,J. Med. Chem., 2000, vol. 43, No. 12, 2310-2323.
Bowman et al., “Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU 1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro,”British Journal of Cancer, vol. 84(1), 106-112 (2001).
Brummelkamp, T. R. et al.,Science, 2002, vol. 2

Affiliated with

Also associated with

Rating

Phthalazinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phthalazinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phthalazinone derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4166660